147 related articles for article (PubMed ID: 35485345)
21. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J
J Infect; 2020 Jul; 81(1):e1-e5. PubMed ID: 32171872
[TBL] [Abstract][Full Text] [Related]
22. High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment.
Macías J; Pinilla A; Lao-Dominguez FA; Corma A; Contreras-Macias E; González-Serna A; Gutierrez-Pizarraya A; Fernández-Fuertes M; Morillo-Verdugo R; Trigo M; Real LM; Pineda JA
Sci Rep; 2020 Dec; 10(1):20958. PubMed ID: 33262433
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical Trial.
Nekoukar Z; Ala S; Moradi S; Hill A; Davoudi Badabi AR; Alikhani A; Alian S; Moghimi M; Shabani AM; Abbaspour Kasgari H
Iran J Pharm Res; 2021; 20(4):278-288. PubMed ID: 35194446
[TBL] [Abstract][Full Text] [Related]
24. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
Simpson KN; Pei PP; Möller J; Baran RW; Dietz B; Woodward W; Migliaccio-Walle K; Caro JJ
Pharmacoeconomics; 2013 May; 31(5):427-44. PubMed ID: 23620210
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
Joseph BA; Dibas M; Evanson KW; Paranjape G; Vegivinti CTR; Selvan PT; Saravu K; Gupta N; Pulakurthi YS; Keesari PR; Varsha S; Chittajallu S; Dmytriw AA; Reierson NL; Mikoff N; Kamrowski S; Schmidt M; Davis AR; Pederson JM; Mishra HK; Touchette JC; Kallmes K
Expert Rev Anti Infect Ther; 2021 Jun; 19(6):679-687. PubMed ID: 33187459
[No Abstract] [Full Text] [Related]
26. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
Wu L; Zheng Y; Liu J; Luo R; Wu D; Xu P; Wu D; Li X
Aging (Albany NY); 2021 Apr; 13(8):10833-10852. PubMed ID: 33879634
[TBL] [Abstract][Full Text] [Related]
27. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
Meriglier E; Rivoisy C; Hessamfar M; Bernard N; Aureau I; Lapoirie J; Contis A; Sacher F; Sacristan B; Lahouati M; Pedeboscq S; Vandenhende MA; Bouchet S; Bonnet F
J Antimicrob Chemother; 2021 Jan; 76(2):482-486. PubMed ID: 33221868
[TBL] [Abstract][Full Text] [Related]
28. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM
BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425
[TBL] [Abstract][Full Text] [Related]
29. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K;
Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703
[TBL] [Abstract][Full Text] [Related]
30. [The efficacy and safety of lopinavir/ritonavir and arbidol in patients with coronavirus disease 2019].
Wen CY; Xie ZW; Li YP; Deng XL; Chen XT; Cao Y; Ou X; Lin WY; Li F; Cai WP; Li LH
Zhonghua Nei Ke Za Zhi; 2020 Aug; 59(8):605-609. PubMed ID: 32388937
[No Abstract] [Full Text] [Related]
31. Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
Echarte-Morales J; Minguito-Carazo C; Del Castillo-García S; Borrego-Rodríguez J; Rodríguez-Santamarta M; Sánchez-Muñoz E; Bergel-García R; González-Maniega C; Prieto-González S; Menéndez-Suarez P; Tundidor-Sanz E; Benito-González T; Fernández-Vázquez F
J Electrocardiol; 2021; 64():30-35. PubMed ID: 33307378
[TBL] [Abstract][Full Text] [Related]
32. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.
Brandariz-Nuñez D; Correas-Sanahuja M; Guarc E; Picón R; García B; Gil R
Med Clin (Barc); 2020 Oct; 155(7):281-287. PubMed ID: 32718719
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
34. Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.
Foglia E; Bonfanti P; Rizzardini G; Bonizzoni E; Restelli U; Ricci E; Porazzi E; Scolari F; Croce D
PLoS One; 2013; 8(2):e57777. PubMed ID: 23460905
[TBL] [Abstract][Full Text] [Related]
35. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
[TBL] [Abstract][Full Text] [Related]
36. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.
Ye XT; Luo YL; Xia SC; Sun QF; Ding JG; Zhou Y; Chen W; Wang XF; Zhang WW; Du WJ; Ruan ZW; Hong L
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3390-3396. PubMed ID: 32271456
[TBL] [Abstract][Full Text] [Related]
37. Smartphone electrocardiogram for QT interval monitoring in Coronavirus Disease 2019 (COVID-19) patients treated with Hydroxychloroquine.
Andy Ko TY; Chen LS; Pang IX; Ling HS; Wong TC; Sia Tonnii LL; Koh KT
Med J Malaysia; 2021 Mar; 76(2):125-130. PubMed ID: 33742617
[TBL] [Abstract][Full Text] [Related]
38. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.
Guner R; Hasanoglu I; Kayaaslan B; Aypak A; Akinci E; Bodur H; Eser F; Kaya Kalem A; Kucuksahin O; Ates I; Bastug A; Tezer Tekce Y; Bilgic Z; Gursoy FM; Akca HN; Izdes S; Erdem D; Asfuroglu E; Hezer H; Kilic H; Cıvak M; Aydogan S; Buzgan T
J Infect Public Health; 2021 Mar; 14(3):365-370. PubMed ID: 33647553
[TBL] [Abstract][Full Text] [Related]
39. Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa.
Meyers T; Sawry S; Wong JY; Moultrie H; Pinillos F; Fairlie L; van Zyl G
Pediatr Infect Dis J; 2015 Feb; 34(2):175-9. PubMed ID: 25741970
[TBL] [Abstract][Full Text] [Related]
40. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
Gourieux B; Reisz F; Belmas AS; Danion F; Fourtage M; Nai T; Reiter-Schatz A; Ruch Y; Walther J; Nivoix Y; Michel B
Eur J Hosp Pharm; 2021 Sep; 28(5):242-247. PubMed ID: 33239282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
